1: Correction for Smolen et al., Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2024 Jun 18;121(25):e2410435121. doi: 10.1073/pnas.2410435121. Epub 2024 Jun 13. Erratum for: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21. doi: 10.1073/pnas.0508776103. 2: Yadav AK, Wang S, Shin YM, Jang BC. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells. Int J Mol Sci. 2024 Mar 1;25(5):2871. doi: 10.3390/ijms25052871. 3: Redmer T, Schumann E, Peters K, Weidemeier ME, Nowak S, Schroeder HWS, Vidal A, Radbruch H, Lehmann A, Kreuzer-Redmer S, Jürchott K, Radke J. MET receptor serves as a promising target in melanoma brain metastases. Acta Neuropathol. 2024 Feb 22;147(1):44. doi: 10.1007/s00401-024-02694-1. Erratum in: Acta Neuropathol. 2024 Mar 27;147(1):63. doi: 10.1007/s00401-024-02719-9.
合成参考文献
参考文献:10.1016/j.ejmech.2015.12.016 摘要:Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. European Journal of Medicinal Chemistry. 2016 Jan;108():495–504. doi: 10.1016/j.ejmech.2015.12.016.